ELBA

European Liquid Biopsy Academy

Towards widespread clinical application of blood-based diagnostic tools.

The European Liquid Biopsy Academy (ELBA) project is an Innovative Training Network (ITN), funded under the European Commission’s Marie Sklodowska-Curie Programme, aiming to move the promising technology of liquid biopsies out of its infancy and bring it to the clinic with a further focus on Non-Small Cell Lung Cancer (NSCLC) early diagnosis. Liquid biopsies offer a minimally invasive, safe, and sensitive alternative or complementary approach for tissue biopsies, which can be a game-changer in cancer management.

Platelets

cfDNA

Circulating
tumor cells

Extracellular
vesicles

Blood is proven to be a valuable medium of biosources. Blood tests can potentially provide extensive information on the molecular landscapes of cancer. Currently, blood-based biopsy measurements focus on four main biosources.

THE TEAM

European Liquid Biopsy Academy’s objective is to expand researchers limited knowledge on what it takes to bring such technology to the market by entrenching and forging the regulatory requirements. Such purpose demands the widespread recruitment of creative next-generation researchers, from different disciplines and sectors, with an innovative mindset that knows how to circumvent the obstacles on the liquid biopsy development and bring such technology to the commercialization path.

Biomarker discovery and assay development

Data analysis
and integration

Diagnostic tests standardization

Clinical
implementation

What's new